Answers are grounded in this paper and cite their sources.
Speckle-type POZ protein (SPOP) mutations define a molecular subtype of prostate cancer, but their genomic and transcriptional features across racially diverse populations remain incompletely resolved. We integrated tumor genomic profiles from 273 patients, including 40 SPOP-mutant tumors, with RNA sequencing from 102 cases to characterize SPOP-associated alterations across disease stage and self-reported race. SPOP-mutant tumors showed significant enrichment of APC and other recurrent co-alterations, supporting Wnt pathway dysregulation as a defining genomic feature. Transcriptomic analysis revealed enhanced proliferative, metabolic, and biosynthetic programs accompanied by suppression of extracellular matrix, structural, and differentiation-associated pathways. Race-stratified analyses identified a conserved repression of structural programs but divergent transcriptional activation states: African American SPOP-mutant tumors preferentially exhibited inflammatory, hypoxic, and epithelial plasticity programs, whereas Caucasian tumors showed stronger MYC, oxidative phosphorylation, translational, and androgen-response signatures. These findings define SPOP-mutant prostate cancer as a molecularly distinct, context-dependent disease subtype with potentially heterogeneous, clinically relevant therapeutic vulnerabilities across patient populations.
No takes yet. Share an insight, caveat, or question.
Rizwan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: